Dry Age-Related Macular Degeneration Market
The dry age-related
macular degeneration AMD market size is expected to cross USD
17.92 Billion by 2032 at a CAGR of 8.2% during the forecast period. This
degenerative eye disease is caused by the thinning of the macula and interferes
with a clear vision in the elderly. The macula is part of the retina that
facilitates clear vision; when this part of the eye deteriorates, it causes
blurred or distorted vision. But this does not mean that the individual will
lose his or her sight, only the central vision is affected by this degenerative
disease, and the peripheral vision remains intact. Vision loss is slow and can
be corrected using innovative ocular treatments. It has been estimated that the
Dry Age-Related Macular Degeneration Market has seen a jump due to increased
research in drugs, rising amount of COVID-19 cases among the old and
age-restricted chronic diseases.
The
Dry Age-Related Macular Degeneration (AMD) market is witnessing a surge in
activity driven by advancements in dry macular
degeneration treatment options. As the population ages, the prevalence of AMD,
particularly the dry form, continues to rise, presenting a significant unmet
medical need. This has spurred intensive research and development efforts
focused on innovative therapies aimed at halting or slowing disease
progression. Companies within the pharmaceutical and biotechnology sectors are
investing heavily in novel treatment modalities, including gene therapies, stem
cell therapies, and targeted drug delivery systems, to address the complex pathophysiology
of dry AMD.
Moreover,
the landscape of the dry macular degeneration treatment market is evolving with
the emergence of personalized medicine approaches. Precision medicine
strategies, leveraging genetic testing and molecular profiling, are being
explored to tailor therapies to individual patients based on their genetic
predispositions and disease characteristics. This personalized approach holds
promise for improving treatment outcomes and reducing the burden of AMD-related
vision loss. Additionally, advancements in diagnostic technologies, such as
optical coherence tomography (OCT) and artificial intelligence (AI)-powered
imaging algorithms, are enhancing early detection and monitoring of dry AMD,
facilitating timely intervention and management strategies. Collectively, these
developments are reshaping the dry AMD market, offering new hope for patients
and driving growth opportunities for stakeholders in the healthcare industry.
Key Players
List
of Dry Age-Related
Macular Degeneration Players Covered in this report:
Santen Pharmaceuticals Inc. (Japan),
Allergan plc (Ireland),
Bausch Health (Canada),
Alimera Science Inc. (US),
Phio Pharmaceuticals Corp (US),
Ocumension Therapeutics Co. Ltd (China),
Belite Bio Inc. (US),
Kubota Vision Inc. (US),
Iveric Bio (US),
Eyestem Research Pvt Ltd (India),
Yuyang DNU Co., Ltd (South Korea),
Stealth Biotherapeutics Inc. (US)
Segment Analysis
The
global Dry Age-Related Macular Degeneration Market Insights has been
divided based on stages, age group, route of administration, diagnosis&
treatment, and end user.
The
market, based on stages, has been segregated into early age-related macular
degeneration, intermediate age-related macular degeneration, and late
age-related macular degeneration.
Based
on age group, the dry AMD market has been divided into above 75 years, above 60
years, and above 40 years.
Based
on diagnosis & treatment, the dry AMD market has been divided into
treatment and diagnosis.
Treatment
type is further bifurcated into nutrition therapy and telescopic lens implant.
Nutrition therapy is again divided into antioxidants and others. Antioxidants
areal so segregated as vitamins, zinc, copper, omega-3 fatty acids, and others.
Diagnosis
is bifurcated into fluorescein angiogram, preliminary test, optical coherence
tomography, and others.
Based
on route of administration, the market is bifurcated into oral, intravitreal,
and others.
On
the basis of end user, the market is bifurcated into hospitals and clinics,
diagnostic centers, academic research institutes, and others
Dry Age-Related Macular Degeneration Market Share
It
has been reported by the American Academy of Ophthalmology that about 11
million people over the age of fifty experience blindness as a result of AMD.
Hence making it a supple market for AMD related treatments. Obesity-related
macular degeneration is also on the rise in North America, along with high
blood pressure from an erratic lifestyle.
Advances
in research and development in Europe and Asia-Pacific have enabled more
patients to see more clearly. The African continent, particularly the Sahara
subcontinent, has experienced a significant increase in dry age-related macular
degeneration due to lack of vitamin A and poor dietary standards. Thus making
this region the key player for pharmaceutical companies to invest in.
The
key companies that are invested into creating feasible solutions for AMD are
Pfizer, Bayer AG, Regenron Pharmaceutical Inc., GlaxoSmithKline plc, and
Novartis AG.
Dry Age-Related Macular Degeneration Market Growth
The
Dry Age-Related Macular Degeneration Market Outlook is led by dry and wet drug
solutions that treat this degenerative disease. Wet age-related AMD will soon
see a jump of 95% in the year 2022. After the impact of COVID-19, it has been
observed that wet macular degeneration has affected most of the ageing
population. In this type, there is an atypical growth of blood vessels beneath
the retina, causing it to bleed create vision obstruction. Developed countries
have introduced intraocular anti-VEGF injections for patients suffering from
wet AMD, thus increasing treatment capacity globally.
In
recent years, Stargardt disease, a genetically inherited retinal disorder
that has become dominant among the younger population, has given impetus for
research towards macular degeneration drugs.
Lucentis,
Avastin, Eylea and Visudyne are some of the prominent drugs available in the
market to treat dry age-related macular degeneration. The Lucentis market has
grown rapidly in developed countries since the government introduced healthcare
benefits for the elderly through affordable treatments.
Dry Age-Related Macular Degeneration Market Value
It
has been noted that off-label drugs are getting more popular due to their
affordability than on-label drugs to treat AMD. An off-label drug like Avastin
is sold rapidly in the market for patients who can get treated within their
income budget.
On
a case-by-case basis, the market is segmented into intravenous and
intravitreous. It is said that the intravitreal segment dominates the market
because it is most effective because of the targeted distribution of drugs.
Furthermore, the majority of anti-VEGF injections are given intravitreally or
intraocular.
Related Reports-
Automated Cell Culture
Equipment
For more information, Please Visit us @ Market Research Future
